155 related articles for article (PubMed ID: 38611075)
1. Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV-A National Cancer Database (NCDB) Study.
Wieland CM; Tuin AM; Dort EJ; Hall AG; Krishnan M; Velagapudi M
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611075
[TBL] [Abstract][Full Text] [Related]
2. Readmission rates in HIV-associated burkitt lymphoma patients in the USA: a nationwide readmission database (NRD) analysis.
Tuin AM; Wieland CM; Dort EJ; Dilsaver DB; Velagapudi M
AIDS Res Ther; 2023 Nov; 20(1):79. PubMed ID: 37951907
[TBL] [Abstract][Full Text] [Related]
3. Primary Thyroid Lymphoma: An Analysis of the National Cancer Database.
Vardell Noble V; Ermann DA; Griffin EK; Silberstein PT
Cureus; 2019 Feb; 11(2):e4088. PubMed ID: 31057992
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
5. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.
Opie J; Antel K; Koller A; Novitzky N
Ann Hematol; 2020 Mar; 99(3):571-578. PubMed ID: 31955214
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
Oriol A; Ribera JM; Bergua J; Giménez Mesa E; Grande C; Esteve J; Brunet S; Moreno MJ; Escoda L; Hernandez-Rivas JM; Hoelzer D
Cancer; 2008 Jul; 113(1):117-25. PubMed ID: 18457327
[TBL] [Abstract][Full Text] [Related]
7. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
[TBL] [Abstract][Full Text] [Related]
8. Stable Incidence and Poor Survival for HIV-Related Burkitt Lymphoma Among the US Veteran Population During the Antiretroviral Era.
Clark E; Royse KE; Dong Y; Chang E; Raychaudhury S; Kramer J; White DL; Chiao E
J Acquir Immune Defic Syndr; 2020 May; 84(1):18-25. PubMed ID: 32251095
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
[No Abstract] [Full Text] [Related]
10. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
[TBL] [Abstract][Full Text] [Related]
11. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.
Gopal S; Patel MR; Yanik EL; Cole SR; Achenbach CJ; Napravnik S; Burkholder GA; Reid EG; Rodriguez B; Deeks SG; Mayer KH; Moore RD; Kitahata MM; Eron JJ; Richards KL
J Natl Cancer Inst; 2013 Aug; 105(16):1221-9. PubMed ID: 23892362
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry.
Burns EA; Wilson JJ; Mathur S; Kieser R; Gong Z; Hu CA; Tang CA; Petkova J; Yuen C; Mai H; Shah S; Rice L; Ganguly S; Pingali SR
Ann Hematol; 2023 Oct; 102(10):2753-2763. PubMed ID: 37422592
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
16. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
Lim KJC; Di Ciaccio P; Polizzotto MN; Milliken S; Cochrane T; Goh Z; Shaw B; Perry E; Gilbertson M; Kermode W; Cheah CY; Latimer M; Hamad N; Ku M
Br J Haematol; 2023 Jun; 201(5):865-873. PubMed ID: 36866733
[TBL] [Abstract][Full Text] [Related]
18. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
[TBL] [Abstract][Full Text] [Related]
19. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.
Rodrigo JA; Hicks LK; Cheung MC; Song KW; Ezzat H; Leger CS; Boro J; Montaner JS; Harris M; Leitch HA
Adv Hematol; 2012; 2012():735392. PubMed ID: 22190945
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection.
Orem J; Maganda A; Mbidde EK; Weiderpass E
Pediatr Blood Cancer; 2009 Apr; 52(4):455-8. PubMed ID: 18802952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]